Demographic Characteristics and Smoking Severity at entry into the SALOME Study Scott MacDonald 1, Eugenia Oviedo-Joekes 2,3, Kirsten Marchand 2,3, Daphne.

Slides:



Advertisements
Similar presentations
Client satisfaction and perceptions of treatments in the North American Opiate Medication Initiative Kirsten Marchand, MSc Candidate at UBC SPPH Canadian.
Advertisements

Chronically Medically Ill Homeless Women: Characteristics at Baseline Romina Kee MD, MPH Collaborative Research Unit John H. Stroger Hospital CRU.
Functional health benefits for elderly people related to social tourism policy promotion Online Conference on Multidisciplinary Social Sciences
Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.
Correlates of polydrug use among injection drug users: The role of socioeconomic stress and quality of life Marrero CA, Robles RR, Reyes JC, Matos TD,
® Introduction Low Back Pain and Physical Function Among Different Ethnicities Adelle A Safo, Sarah Holder DO, Sandra Burge PhD The University of Texas.
HIV Risk Behaviors and Alcohol Intoxication among Injection Drug Users in Puerto Rico Tomás D. Matos, MS Center for Addiction Studies Universidad Central.
Dejar de Fumar Hoy - Quit Smoking Now: A Smoking Cessation Program for Latinos Sally Haack, Pharm.D., BCPS; Naomi Barasch, Pharm.D. Candidate Drake University.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
BACKGROUND & OBJECTIVES Approximately 1 in 20 U.S. adults age 50 and over have depression 1 More than half of these older adults have depression with severe.
Killing the Pain: Prescription Drug Abuse and Other Risky Behaviors in Rural Appalachia Jennifer R. Havens, PhD, MPH Department of Behavioral Science Center.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2010.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,
® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.
Audrey J. Brooks, PhD University of Arizona CA-AZ node.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
® Introduction Back Pain Flare Ups, Physical Function, and Opioid Use Adriana Gonzalez, Darryl White MD, Sandra Burge PhD The University of Texas Health.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
Acknowledgments: Data for this study were collected as part of the CIHR Team: GO4KIDDS: Great Outcomes for Kids Impacted by Severe Developmental Disabilities.
Neighborhood factors and quitting smoking in Ontario Presented by: Sarah Edwards *, Susan Bondy *, Russell Callaghan †,*, Robert Mann ‡,* * Dalla Lana.
® From Bad to Worse: Comorbidities and Chronic Lower Back Pain Margaret Cecere JD, Richard Young MD, Sandra Burge PhD The University of Texas Health Science.
American Association for the Treatment of Opioid Dependence, Inc National Conference, Atlanta April 25, 2006 Evaluation of the Impact of Opioid Treatment.
Prevalence of Chronic Disease & Comorbid Conditions in the CHAIN Cohort CHAIN Report Peter Messeri, Gunjeong Lee, Sara Berk Mailman School of Public.
Can undergoing an internet based ACT intervention change the impact of predictors thought to lead to Substance Use? Leonidou. G., Savvides. S., N. & Karekla.
MRCPsych seminar series Epidemiology of addictive disorders: a brief review Dr Stuart McLaren March 2010.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2012.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
Obtaining housing associated with achieving abstinence after detoxification in adults with addiction Tae Woo Park, Christine Maynié-François, Richard Saitz.
Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.
CARIBBEAN BASIN AND HISPANIC ADDICTION TECHNOLOGY TRANSFER CENTER Effects of a Two-facet Intervention to Reduce HIV Risk Behaviors Among Hispanic Drug.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009.
CCTN September 6 th, Recent Scientific Publications from the Clinical Trials Network David Liu, M.D. (CTN-0029) Harold Perl, Ph.D. (CTN-0015) Paul.
The correlation between clinical and histopathological diagnosis in adults with chronic tonsillitis. Author: Adelina Huza 6th year student - General Medicine.
Participants were recruited from 6 drug free, psychosocial treatment (PT) and 5 methadone maintenance (MM) programs (N = 628) participating in a NIDA Clinical.
Introduction Introduction Alcohol Abuse Characteristics Results and Conclusions Results and Conclusions Analyses comparing primary substance of abuse indicated.
Doctors In Turkey Smoke More SAHIN EM, OZER C, DAGDEVIREN N, AKTURK Z Trakya University Faculty of Medicine Department of Family Practice.
SCHOOL OF NURSING UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Not Ready for Prime Time? A Web-Based SBIRT Intervention in an Urban Safety-Net HIV Clinic Carol.
Role of harm reduction in HCV prevention in France: from research to scale up Bruno Spire & Patrizia Carrieri.
Fourth Year Follow-up of Assistive Devices Intervention Study Among the Home-Based Elderly Shin-yi Lin, MS Machiko R. Tomita, Ph. D. Linda F. Fraas, MA,
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Zach Walsh University of British Columbia This study examined the use of cannabis as a substitute for alcohol and other psychoactive.
CEACEA CENTROCENTRO DE ESTUDIOS EN ADICCION Testing an Intervention Model to Reduce HIV/AIDS Among Hispanic Drug Users Residing in Puerto Rico Robles RR,
Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.
® Changes in Opioid Use Over One Year in Patients with Chronic Low Back Pain Alejandra Garza, Gerald Kizerian, PhD, Sandra Burge, PhD The University of.
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
Grace Scott, MSc 1, Dr. Hosam Amoodi, MD 2, Dr. Damian Micomonaco, MD 2 1 Graduate Program in Health and Rehabilitation Sciences, _Western University 2.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Clinical Trial Finds That While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use Among Those Dependent on Prescription Opioids, 91% Were Not.
SARAH M. BAGLEY, MD ASSISTANT PROFESSOR OF MEDICINE AND PEDIATRICS BOSTON UNIVERSITY SCHOOL OF MEDICINE AMERSA ANNUAL CONFERENCE NOVEMBER 5, 2015 Overdose.
Factors associated with concurrent Heroin use among patients on Methadone maintenance treatment in Vietnam from 2008 to 2013 Hoang Nam Thai MD, MPH – CDC/DGHT.
The authors would like to acknowledge the families at the Children’s Hospital of Wisconsin Jane P. Pettit Pain and Palliative Care Center. For more information,
Janet H. Van Cleave PhD, RN1 Brian Egleston PhD2
Efficacy of Combination First Line Agents for Smoking Cessation Sneha Baxi, Pharm.D. Pharmacy Practice Resident University of Illinois at Chicago.
Reaching Tobacco Treatment Providers Through Online Training INTRODUCTION  U.S. Public Health Service Guidelines recommend that health care professionals.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Twelve Month Follow-Up of Mothers from the ‘Child Protection and Mothers in Substance Abuse Treatment Study’ Stephanie Taplin PhD, Rachel Grove & Richard.
Clare Meernik, MPH 1 ; Anna McCullough, MSW, MSPH, CTTS 1 ; Leah Ranney, PhD 1 ; Barbara Walsh 2 ; Adam O. Goldstein, MD, MPH 1 Predictors of Quit for.
Trends in Access to Substance Abuse Treatment for Women and Men: Jeanne C. Marsh, PhD, Hee-Choon Shin, PhD, Dingcai Cao, PhD University of Chicago.
Hatch-Maillette, M. 1, Calsyn, D. A1,2, Doyle, S. 1, Woods, A
Alcohol, Other Drugs, and Health: Current Evidence
Characteristics and response to treatment among Indigenous people receiving injectable opioids for the treatment of long-term opioid-dependence Heather.
MHEALTH to Improve Health: Effectiveness of a weekly text messaging intervention to improve ART adherence and HIV Viral Load: WelTel OAKTREE. M.C.M. Murray1,2,3,
The relationship between incarceration and opioid addiction treatment
Public Health Implications
Presentation transcript:

Demographic Characteristics and Smoking Severity at entry into the SALOME Study Scott MacDonald 1, Eugenia Oviedo-Joekes 2,3, Kirsten Marchand 2,3, Daphne Guh 3 (1) Providence Health Care, Crosstown Clinic (2) School of Population and Public Health, University of British Columbia (3) Centre for Health Evaluation and Outcome Sciences Conclusions Background Objectives Results Table 2. Mean smoking severity score by demographic characteristics at baseline References Contact Information Studies in Europe and Canada 1,2,3 have demonstrated that injectable diacetylmorphine (the active ingredient in heroin), provided in specialized clinics, is effective at engaging and retaining the most vulnerable street heroin injectors in treatment. Due to the political restrictions around the prescription of diacetylmorphine, alternatives are needed. Such an alternative could be injectable hydromorphone (a licensed pain medication). This group of illicit heroin users has a high degree of tobacco use. The morbidity associated with their tobacco use could affect outcomes and participation in opioid substitution treatment. The aim of this baseline analysis was to describe participants' smoking severity at entry into a study of injectable diacetylmorphine and hydromorphone and to identify characteristics associated with smoking severity. Methods and Analysis Design : The Study to Assess Long-term Opioid Medication Effectiveness (SALOME) was a two-stage phase III, single site (Vancouver, Canada), randomized double blind controlled trial. SALOME was designed to test if hydromorphone was as effective as diacetylmorphine for the treatment of long-term illicit opioid injection. Study sample : SALOME randomized a total of 202 men and women with chronic, long-term opioid dependence. At treatment entry, participants were current illicit injection opioid users and had at least one previous episode of opioid maintenance treatment. Data collection: Baseline questionnaires were collected by an independent research team and measured demographic, substance use, and health status. The main outcome variable of interest, smoking severity, was measured using the Fagerstrom Test for Nicotine Dependence 4. Data analysis: Data were measured with descriptive statistics. Continuous variables were described with mean ± SD and categorical variables were described by frequencies and percentages. To test the relationship between baseline demographic characteristics and Fagerstrom score, independent t-tests were used. Dr. Scott MacDonald, Physician Lead, Providence Crosstown Clinic 84 West Hastings Street Vancouver, BC V6B 1G6 1) Oviedo-Joekes, E., Brissette, S., Marsh, D. C., Lauzon, P., Guh, D., Anis, A., & Schechter, M. T. (2009). Diacetylmorphine versus methadone for the treatment of opioid addiction. New England Journal of Medicine, 361 (8), ) Van den Brink, W., Hendriks, V. M., Blanken, P., Koeter, M. W., van Zwieten, B. J., & Van Ree, J. M. (2003). Medical prescription of heroin to treatment resistant heroin addicts: two randomized controlled trials. Bmj, 327 (7410), ) March, J. C., Oviedo-Joekes, E., Perea-Milla, E., & Carrasco, F. (2006). Controlled trial of prescribed heroin in the treatment of opioid addiction. Journal of substance abuse treatment, 31 (2), ) Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K. (1991). The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction, 86 (9), This is a group of patients with severe opiate use disorder as well as concurrent chronic disease, including smoking disease. Their severe symptomatology may be mitigated by smoking cessation. This analysis suggests there is a group of injectable opioid assisted treatment (iOAT) recipients who could benefit from intensified programs such as the Ottawa Smoking Cessation Model. Future analysis may show improvement in this group of patients in whom smoking is often ignored as an important intervention. Table 1 and Figure 1 present the proportion of participants in baseline Fagerstrom severity score category groups. Several baseline characteristics at baseline entry to SALOME are presented here, including: gender, education, age, and crack cocaine use (see table 2). The only characteristic which showed a statistically significant difference was self-reported chronic disease. These data show that study participants who self- reported chronic disease on enrolment had significantly higher smoking dependence (Mean Fagerstrom score = 4.73 [SD=2.34]) compared to those without chronic disease (Mean Fagerstrom score = 3.95 [SD=2.51]) (p<0.028). CharacteristicsFagerstrom Score Total Sample 4.40 ± 2.44 Women 4.31 ± 2.51 Men 4.44 ± 2.41 Less than 40 years old 4.81 ± years or older 4.24 ± 2.42 Non-Aboriginal ethnicity 4.21 ± 2.43 Aboriginal ethnicity 4.84 ± 2.42 Less than high school education 4.64 ± 2.32 High school education or higher 4.19 ± 2.53 Has a self-reported chronic condition * 4.73 ± 2.34 No self-reported chronic conditions * 3.95 ± 2.51 HIV Positive 4.25 ± 2.58 HIV Negative 4.43 ± 2.42 Hepatitis C Positive 4.45 ± 2.46 Hepatitis C Negative 4.08 ± 2.32 Using crack cocaine 4.59 ± 2.28 No crack cocaine use4.08 ± 2.67 Table 1: Fagerstrom smoking severity score groups Smoking Severity Score Group Number of participants (%) Not currently smoking (Score= 0) 17 (8.95) Low dependence (Score= 1-2)30 (15.79) Low to moderate dependence (Score= 3-4)35 (18.42) Moderate dependence (Score= 5-7)94 (49.47) High dependence (Score= 8+)14 (7.37) Figure 1. Proportion of participants in smoking severity groups * p < 0.05 n missing = 12